MTOR and neoplasm: Proctor et al. [51] also recently linked mutations in the PI3K/AKT/mTOR pathway to elevated levels of the immune checkpoint proteins PD-L2 and B7-H3, strengthening the evidence that genetic changes can stimulate a different tumour microenvironment.